After Hours
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours.
Stocks Info
Xenon Pharmaceuticals Inc is listed on the NASDAQ as a member of the Healthcare sector and is a part of the Biotechnology industry. The current market capitalization of Xenon Pharmaceuticals Inc is $2.42B. A total of 1.57 million shares were traded on the day, compared to an average of 539.69K shares.
In the most recent transaction, MORTIMER IAN sold 22,468 shares of XENE for 40.20 per share on Jan 24 ’25. After the transaction, the PRESIDENT & CEO now owns 31,302 company shares. In a previous transaction on Jan 27 ’25, MORTIMER IAN sold 16,315 shares at 40.50 per share. XENE shares that PRESIDENT & CEO owns now total 31,302.
Among the insiders who sold shares, MORTIMER IAN disposed of 16,217 shares on Jan 23 ’25 at a per-share price of $40.08. This resulted in the PRESIDENT & CEO holding 31,302 shares of XENE after the transaction. In another insider transaction, IAN MORTIMER bought 16,315 shares at $40.50 per share on Jan 27 ’25.
Though price targets are rarely accurate, they can exert some influence from time to time and were often accepted as valuable by the market. In terms of 52-week highs and lows, XENE has a high of $46.00 and a low of $27.56.
As of this writing, XENE has an earnings estimate of -$0.91 per share for the current quarter. EPS was calculated based on a consensus of 12.0 estimates, with a high estimate of -$0.79 per share and a lower estimate of -$0.98.
Balance Sheet Annually/Quarterly
A balance sheet is a report that shows the company’s assets and liabilities. In addition, it shows how much equity investors have invested in the company. Investors can determine the company’s prospects by calculating its financial ratios based on this information. XENE’s latest balance sheet shows that the firm has $551.77M in Cash & Short Term Investments as of fiscal 2021. There were $8.26M in debt and $14.32M in liabilities at the time. Its Book Value Per Share was $9.88, while its Total Shareholder’s Equity was $550.03M.
Analysts Opinion
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for XENE is Buy with a score of 4.88.
